
Leber's Hereditary Optic Neuropathy - Pipeline Insight, 2025
Description
DelveInsight’s, “Leber’s hereditary optic neuropathy - Pipeline Insight, 2025,” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in Leber’s hereditary optic neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Leber’s hereditary optic neuropathy: Overview
Leber hereditary optic neuropathy (LHON) is often characterized by bilateral, painless subacute loss of central vision during young adult life. In most cases, symptoms begin with one eye first, followed a few weeks later by visual failure in the other eye. Extremely rarely there may be neurologic abnormalities, such as peripheral neuropathy, postural tremor, nonspecific myopathy, and movement disorders. LHON is caused by mutations in mitochondrial DNA and it is strictly transmitted by maternal inheritance.
Individuals with LHON typically display symptoms in their young adult years. If vision is lost, then it usually occurs before 40 years of age. LHON is caused by genetic mutations in the mitochondrial DNA (mtDNA). Some mothers with a LHON gene mutation do not show symptoms, but family history often reveals female relatives with visual loss at an early age.
Affected individuals should receive supportive management and treatment through the usage of visual aids, occupational rehabilitation, and local social services. Small studies have shown that therapies involving ubiquinone and idebenone may provide possible benefits during the acute and chronic phases of the disorder. Affected individuals should avoid smoking and excessive alcohol consumption, which generate reactive oxygen species (ROS) producing mitochondrial impairments.
Report Highlights
This segment of the Leber’s hereditary optic neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Leber’s hereditary optic neuropathy Emerging Drugs
NFS-01 (NR082, rAAV-ND4) was designated as orphan drug by the U.S. FDA in September 2020, which laid a foundation for accelerating international development of this product.
Further product details are provided in the report……..
Leber’s hereditary optic neuropathy: Therapeutic Assessment
This segment of the report provides insights about the different Leber’s hereditary optic neuropathy drugs segregated based on following parameters that define the scope of the report, such as:
Leber’s hereditary optic neuropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Leber’s hereditary optic neuropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leber’s hereditary optic neuropathy drugs.
Leber’s hereditary optic neuropathy Report Insights
Current Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Leber’s hereditary optic neuropathy: Overview
Leber hereditary optic neuropathy (LHON) is often characterized by bilateral, painless subacute loss of central vision during young adult life. In most cases, symptoms begin with one eye first, followed a few weeks later by visual failure in the other eye. Extremely rarely there may be neurologic abnormalities, such as peripheral neuropathy, postural tremor, nonspecific myopathy, and movement disorders. LHON is caused by mutations in mitochondrial DNA and it is strictly transmitted by maternal inheritance.
Individuals with LHON typically display symptoms in their young adult years. If vision is lost, then it usually occurs before 40 years of age. LHON is caused by genetic mutations in the mitochondrial DNA (mtDNA). Some mothers with a LHON gene mutation do not show symptoms, but family history often reveals female relatives with visual loss at an early age.
Affected individuals should receive supportive management and treatment through the usage of visual aids, occupational rehabilitation, and local social services. Small studies have shown that therapies involving ubiquinone and idebenone may provide possible benefits during the acute and chronic phases of the disorder. Affected individuals should avoid smoking and excessive alcohol consumption, which generate reactive oxygen species (ROS) producing mitochondrial impairments.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Leber’s hereditary optic neuropathy R&D. The therapies under development are focused on novel approaches for Leber’s hereditary optic neuropathy.
This segment of the Leber’s hereditary optic neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Leber’s hereditary optic neuropathy Emerging Drugs
- GS 010: GenSight Biologics
- NFS-02: Neurophth Therapeutics
NFS-01 (NR082, rAAV-ND4) was designated as orphan drug by the U.S. FDA in September 2020, which laid a foundation for accelerating international development of this product.
Further product details are provided in the report……..
Leber’s hereditary optic neuropathy: Therapeutic Assessment
This segment of the report provides insights about the different Leber’s hereditary optic neuropathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Leber’s hereditary optic neuropathy
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Leber’s hereditary optic neuropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Leber’s hereditary optic neuropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Leber’s hereditary optic neuropathy drugs.
Leber’s hereditary optic neuropathy Report Insights
- Leber’s hereditary optic neuropathy pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Leber’s hereditary optic neuropathy drugs?
- How many Leber’s hereditary optic neuropathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Leber’s hereditary optic neuropathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Leber’s hereditary optic neuropathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Leber’s hereditary optic neuropathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- GenSight Biologics
- Neurophth Therapeutics
- Mitotech
- Stealth BioTherapeutics
- Fortify Therapeutics
- Neuroptika
- GS 010
- NFS-02
- NFS-01
- Visomitin
- Elamipretide
- Research programme: Leber's hereditary optic neuropathy therapeutics
- NRO-1
Table of Contents
40 Pages
- Introduction
- Executive Summary
- Leber’s hereditary optic neuropathy: Overview
- Structure
- Mechanism of Action
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Leber’s hereditary optic neuropathy– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Leber’s hereditary optic neuropathy companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Leber’s hereditary optic neuropathy Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- Comparative Analysis
- NFS-01: Neurophth Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Visomitin: Mitotech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- NFS-02: Neurophth Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Leber’s hereditary optic neuropathy Key Companies
- Leber’s hereditary optic neuropathy Key Products
- Leber’s hereditary optic neuropathy- Unmet Needs
- Leber’s hereditary optic neuropathy- Market Drivers and Barriers
- Leber’s hereditary optic neuropathy- Future Perspectives and Conclusion
- Leber’s hereditary optic neuropathy Analyst Views
- Leber’s hereditary optic neuropathy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.